Tag Archives: AstraZeneca’s Imfinzi shows promise in treating aggressive lung cancer

AstraZeneca (AZN.L), opens new tab said on Friday its blockbuster cancer drug Imfinzi helped improve overall and progression-free survival in patients with limited-stage small cell lung cancer. The drug demonstrated “statistically significant and clinically meaningful improvement” in the dual primary goals of overall survival and progression-free survival in patients for whom the disease had not worsened following concurrent chemoradiotherapy in …

Read More »